Metraipolis › archive › dc_a19ec8ec4ca2

The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A… — Europe PMC PMID:35951621

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35951621
DOI
10.1371/journal.pone.0272906
License (as archived)
CC0-1.0
Archived
2026-10-17T05:44:09.145Z
SHA-256 of the archived text
c1499bfcaeb659749243f73589f14ff5c47de16d3a5b83237bf57cb141140f4e
Stable URL of this page
https://metraipolis.com/documento/dc_a19ec8ec4ca2

How to cite

The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A… — Europe PMC PMID:35951621 — Europe PMC (en), https://europepmc.org/article/MED/35951621 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a19ec8ec4ca2 (Metraipolis archive dc_a19ec8ec4ca2, sha256 c1499bfcaeb659749243f73589f14ff5c47de16d3a5b83237bf57cb141140f4e)
BibTeX
@misc{dca19ec8ec4ca2,
  title = {The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A… — Europe PMC PMID:35951621},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35951621},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a19ec8ec4ca2; sha256 c1499bfcaeb659749243f73589f14ff5c47de16d3a5b83237bf57cb141140f4e},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35951621. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Human immunodeficiency virus (HIV) remains a global health threat, especially in developing countries. The successful scale-up of antiretroviral therapy (ART) programs to address this threat is hindered by a high proportion of patient loss to follow-up (LTFU). LTFU is associated with poor viral suppression and increased mortality. It is particularly acute among adolescents, who face unique adherence challenges. Although LTFU is a critical obstacle on the continuum of care for adolescents, few regional-level studies report the proportion of LTFU among adolescents receiving ART. Therefore, a systematic review and meta-analysis were conducted to estimate the pooled LTFU in ART programs among adolescents living with HIV in sub-Saharan Africa (SSA). Methods: We searched five databases (PubMed, Embase (Elsevier), PsycINFO, CINAHL, and Scopus) for articles published between 2005 and 2020 and reference lists of included articles. The PRISMA guidelines for systematic reviews were followed. A standardised checklist to extract data was used. Descriptive summaries were presented using narrative tables and figures. Heterogeneity within the included studies was examined using the Cochrane Q test statistics and I2 test. Random effect models were used to estimate the pooled prevalence of LTFU among ALHIV. We used Stata version 16 statistical software for our analysis. Results: Twenty-nine eligible studies (n = 285,564) were included. An estimated 15.07% (95% CI: 11.07, 19.07) of ALHIV were LTFU. Older adolescents (15-19 years old) were 43% (AOR = 0.57, 95% CI: 0.37, 0.87) more likely to be LTFU than younger (10-14 years old) adolescents. We find an insignificant relationship between gender and LTFU (AOR = 0.95, 95% CI: 0.87, 1.03). A subgroup analysis found that regional differences in the proportion of adolescent LTFU were not statistically significant. The trend analysis indicates an increasing proportion of adolescent LTFU over time. Conclusions and recommendations: The proportion of LTFU among HIV-positive adolescents in SSA seems higher than those reported in other regions. Older adolescents in the region are at an increased risk for LTFU than younger adolescents. These findings may help policymakers develop appropriate strategies to retain ALHIV in ART services. Such strategies could include community ART distribution points, appointment spacing, adherence clubs, continuous free access to ART, and community-based adherence support.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-08-11).
Identificativi: PMID 35951621 · PMCID PMC9371308 · DOI 10.1371/journal.pone.0272906.
Descrittori MeSH principali: HIV Infections; HIV Seropositivity; Anti-HIV Agents.
Pagina: https://europepmc.org/article/MED/35951621 — https://doi.org/10.1371/journal.pone.0272906. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-17T05:13:41.335Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.